SLAM
KRYS icon

Swiss Life Asset Management’s Krystal Biotech KRYS Stock Holding History

Swiss Life Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$794K Sell
2,136
-29
-1% -$8.66K ﹤0.01% 772
2026
Q1 		$559K Buy
2,165
+1,174
+118% +$312K ﹤0.01% 823
2025
Q4 		$244K Buy
+991
New +$209K ﹤0.01% 1148

Other funds holding KRYS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Swiss Life Asset Management's KRYS Position: Q2 2026 in Review

Swiss Life Asset Management reduced its Krystal Biotech (KRYS) stake by 1.3% in Q2 2026, selling an estimated $8.66K and leaving 2,136 shares worth $794K. The position accounts for ﹤0.01% of the portfolio, ranked #772.

Swiss Life Asset Management first reported a position in KRYS in Q4 2025 and has held it in 3 quarters since. 272 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Swiss Life Asset Management held 2,136 shares of Krystal Biotech worth $794K as of Q2 2026.
  • Swiss Life Asset Management sold 29 Krystal Biotech shares in Q2 2026, an estimated $8.66K.
  • Krystal Biotech made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #772 holding.
  • Swiss Life Asset Management first reported a position in Krystal Biotech in Q4 2025 and has held it in 3 quarters since.
  • 272 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.